reglab/statecodes huggingface dataset:
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 23 - ACCOUNTING FOR PRESCRIPTION DRUGS › Section 392-4-23-3 - Reporting of Theft, Loss and Unresolved Inventory Discrepancies of Controlled Drugs

Current through 2024-29, July 17, 2024
A pharmacist shall report any significant theft, loss or
					 unresolved inventory discrepancy of controlled drugs to the board. The
					 pharmacist shall make the report no later than 7 days after discovery of the
					 theft, loss or inventory discrepancy. The report may be made via letter,
					 facsimile transmission or email, must be signed by the pharmacist in charge or
					 other pharmacist with knowledge of the situation, and must list the controlled
					 drugs and quantities of same that were lost or stolen or cannot be accounted
					 for. A pharmacist may satisfy the reporting obligation for controlled
					 substances by filing Form 106 with the DEA and sending a copy to the
					 board.
When determining if a theft, loss or unresolved inventory
					 discrepancy is "significant," a pharmacist should consider, among others, the
					 following factors:
1. The actual
				  quantity of controlled substances lost in relation to the type of
				  business;
2. The specific
				  controlled substances lost;
3.
				  Whether the loss of the controlled substances can be associated with access to
				  those controlled substances by specific individuals, or whether the loss can be
				  attributed to unique activities that may take place involving the controlled
				  substances;
4. A pattern of losses
				  over a specific time period, whether the losses appear to be random, and the
				  results of efforts taken to resolve the losses; and, if known,
5. Whether the specific controlled substances
				  are likely candidates for diversion; and
6. Local trends and other indicators of the
				  diversion potential of the missing controlled substance.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 24 - RETENTION OF RECORDS BY PHARMACIES › Section 392-4-24-1 - Patient Profiles

Current through 2024-29, July 17, 2024
A pharmacy shall retain each patient profile, including
					 patient profiles maintained on an automated data processing system pursuant to
					 Chapter 19, Section 7 of the board's rules, for 5 years from the date of last
					 entry.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 24 - RETENTION OF RECORDS BY PHARMACIES › Section 392-4-24-2 - Prescription Drug Orders

Current through 2024-29, July 17, 2024
1.
Controlled Drugs - Written or Faxed Prescriptions
A pharmacy shall retain each written or faxed prescription
					 drug order for a controlled drug for 2 years. For manually-processed orders,
					 the retention period begins on the date of first fill. For orders processed by
					 an automatic data processing system, the retention period begins on the date of
					 last fill.
2.
Noncontrolled Drugs; Manual Recordkeeping
A. A pharmacy shall retain each written or
				  faxed prescription drug order for a noncontrolled drug that was manually
				  processed for 2 years from the date of first fill.
B. A pharmacy may retain a scanned or
				  microfiched unadulterated copy of the prescription drug order in place of the
				  original. The scan or microfiche must include any information appearing on the
				  reverse side of the prescription drug order.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 24 - RETENTION OF RECORDS BY PHARMACIES › Section 392-4-24-3 - Central Fill, Central Processing

Current through 2024-29, July 17, 2024
A central fill pharmacy or central processing center shall
					 retain all records relating to the receipt, processing, handling and movement
					 of prescription drug orders and prescription drugs to and from originating
					 pharmacies and dispensing pharmacies, including the audit trail required by
					 Chapter 21, Section
					 5(1) of the board's
					 rules, for 2 years from the date of last fill.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 24 - RETENTION OF RECORDS BY PHARMACIES › Section 392-4-24-4 - All Other Records

Current through 2024-29, July 17, 2024
Unless otherwise specified in these rules, the retention
					 period for all other records that a pharmacist or pharmacy is required to
					 create, including records created by an automated pharmacy system in accordance
					 with Chapter 19, Section 7 of the board's rules, is 2 years from the date of
					 creation.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 24 - RETENTION OF RECORDS BY PHARMACIES › Section 392-4-24-5 - Production at Time of Inspection

Current through 2024-29, July 17, 2024
A pharmacist or pharmacy shall produce to an inspector of
					 the board, upon request of the inspector, any and all records which the
					 pharmacist or pharmacy is required to retain. Production of records for the
					 most recent 12-month period must be made immediately at the time of inspection
					 or investigation. The balance of the records requested must be produced within
					 3 business days of the request.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 25 - PATIENT COUNSELING › Section 392-4-25-1 - New Prescription Drug Orders

Current through 2024-29, July 17, 2024
With each new prescription dispensed, the pharmacist
					 shall:
1.
Review
Review the individual's patient profile for the following
					 potential drug therapy problems:
A.
				  Therapeutic duplication;
B. Drug
				  disease contraindications when such information has been provided to the
				  pharmacist;
C. Drug
				  interactions;
D. Incorrect drug
				  dosage or duration;
E. Drug allergy
				  interactions; and
F. Clinical abuse
				  or misuse.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 25 - PATIENT COUNSELING › Section 392-4-25-2 - Refill Prescription Drug Orders

Current through 2024-29, July 17, 2024
With each refill prescription dispensed, the pharmacist
					 shall offer to counsel the patient on the medication or device being dispensed,
					 or to review with the patient the clinical information provided with the
					 initial dispensing. This offer may be made in the manner determined by the
					 professional judgment of the pharmacist, and may include any one or more of the
					 following:
1. Face-to-face
				  communication with the pharmacist or designee;
2. A notation affixed to or written on the
				  bag in which the prescription is dispensed;
3. A notation contained on the prescription
				  container; or
4. Telephone
				  conversation.
The offer to counsel may be made by a designee of the
					 pharmacist, but only the pharmacist may counsel the patient.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 25 - PATIENT COUNSELING › Section 392-4-25-3 - Refusal to Accept Counseling

Current through 2024-29, July 17, 2024
Nothing in this chapter shall be construed as requiring a
					 pharmacist to provide counseling when the patient, the patient's caregiver or
					 the authorized agent of the patient refuses to accept counseling. The
					 pharmacist shall document the refusal.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 25 - PATIENT COUNSELING › Section 392-4-25-4 - Documentation of Intervention

Current through 2024-29, July 17, 2024
The pharmacist shall record in the patient profile any
					 significant intervention in the patient's medication utilization that has
					 occurred, in the judgment of the pharmacist, as a result of the counseling
					 required by this chapter.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 25 - PATIENT COUNSELING › Section 392-4-25-5 - Patients in Hospital or Institution

Current through 2024-29, July 17, 2024
The obligation to perform or offer counseling set forth in
					 Section
					 1(2) and Section
					 2 of this chapter does not apply to
					 those prescriptions for patients in hospitals or institutions where the
					 medication is to be administered by a nurse or other individual licensed to
					 administer medications or to those prescriptions for patients who are to be
					 discharged from a hospital or institution.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 25 - PATIENT COUNSELING › Section 392-4-25-6 - Opiate Treatment Programs

Current through 2024-29, July 17, 2024
The obligation to perform or offer counseling set forth in
					 Section
					 1(2) and Section
					 2 of this chapter does not apply to
					 prescriptions for opiate agonist treatment medications dispensed at an opioid
					 treatment program licensed by the board pursuant to Chapter 36 of the board's
					 rules. The dispensing pharmacist shall discharge the pharmacist's statutory
					 obligation to offer counseling in connection with new prescriptions by ensuring
					 that written directions for use and other information relating to proper
					 utilization of the medication prescribed are included with each new
					 prescription delivered by the opioid treatment program. The written information
					 must include a telephone number at which the pharmacist in charge may be
					 contacted by patients.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 26 - GENERIC SUBSTITUTION › Section 392-4-26-1 - Generic and Therapeutically Equivalent Drugs

Current through 2024-29, July 17, 2024
1.
Basis for Categorization
A generic and therapeutically equivalent drug, as defined
					 in
					 32 M.R.S.A.
					 §13702(11), is a drug
					 that meets the following criteria:
A.
				  Chemical Equivalents. Drug products that contain the same amounts of the same
				  therapeutically active ingredients in the same dosage forms and that meet
				  present compendial standards.
B.
				  Bioequivalents. Chemical equivalents, which when administered to the same
				  individuals in the same dosage regimen will result in comparable
				  bioavailability.
C. Therapeutic
				  Equivalents. Chemical equivalents, which when administered to the same
				  individuals in the same dosage regimen, will provide essentially the same
				  efficacy and/or toxicity.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 27 - POSSESSION AND ADMINISTRATION OF NONCONTROLLED PRESCRIPTION DRUGS BY NURSES › Section 392-4-27-1 - Possession

Current through 2024-29, July 17, 2024
A registered nurse or advanced practice registered nurse
					 who is an employee of a home health care provider as defined in
					  22 M.R.S.A.
					 §2142(3), or a hospice
					 program or hospice provider as defined in
					  22 M.R.S.A.
					 §8621(10), may possess,
					 in the course of employment, the following noncontrolled prescription
					 drugs:
1. Adrenalin
2. Benadryl
3. Sterile Water
4. Sterile Normal Saline
5. Influenza Vaccines
6. Hepatitis B Vaccine
7. Mantoux Test Kit (for tuberculosis
				  testing)
8. Heparin
9. Pneumonia Vaccine
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 4 - DISPENSING PRESCRIPTION DRUGS › Chapter 27 - POSSESSION AND ADMINISTRATION OF NONCONTROLLED PRESCRIPTION DRUGS BY NURSES › Section 392-4-27-2 - Administration

Current through 2024-29, July 17, 2024
In accordance with
					 
					 32 M.R.S.A. §13810(2),
					 the noncontrolled prescription drugs listed in Section
					 1 of this chapter must be
					 administered in accordance with written protocols approved annually by the
					 employer's professional advisory committee, which must include a physician
					 licensed under Title 32, Chapter 36 or 48. The protocols shall include, at a
					 minimum, guidelines that will ensure the integrity and security of these drugs
					 during transport and when the employee is not on duty.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 28 - ENFORCEMENT AND DISCIPLINARY PROCEDURES › Section 392-5-28-1 - Appeal of License Denial

Current through 2024-29, July 17, 2024
An applicant or licensee may appeal a license denial to
					 the board by filing a request for hearing with the board within 30 days of the
					 applicant's or licensee's receipt of notice of the denial. An adjudicatory
					 hearing will be scheduled upon receipt of a timely appeal. Non-timely appeals
					 will be denied without hearing.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 28 - ENFORCEMENT AND DISCIPLINARY PROCEDURES › Section 392-5-28-2 - Disciplinary Procedure

Current through 2024-29, July 17, 2024
The board will follow the procedures for investigating and
					 processing complaints contained in the Administrative Complaint Procedure
					 followed by the Department of Professional and Financial Regulation, Office of
					 Licensing and Registration for the professional and occupational licensing
					 boards and registration programs administered by OLR.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 29 - VIOLATIONS OF STATE OR FEDERAL LAW OR RULE; OTHER STANDARDS › Section 392-5-29-2 - Incorporation by Reference

Current through 2024-29, July 17, 2024
The board hereby incorporates by reference into this
					 chapter the rule chapters of the FDA, DEA, Federal Trade Commission and
					 Consumer Product Safety Commission specified in Section
					 1(5)-(8) of this
					 chapter and the Utilization Control rule of the Centers for Medicare &
					 Medicaid Services, Department of Health and Human Services specified in Section
					 1(9) of this
					 chapter. Copies of these rules are available at the State Law Library, State
					 House, Augusta, ME 04333, tel. (207 287-1600 and may also be obtained from the
					 U.S. Government Printing Office, FDsys / Federal Digital System, at the
					 following URL-
http://www.gpo.gov/fdsys/
The board hereby incorporates by reference into this
					 chapter the MaineCare Pharmacy Benefits Manual specified in Section
					 1(9) of this
					 chapter. The MaineCare Pharmacy Benefits Manual may be obtained from-
Office of MaineCare Services
Department of Health and Human Services
11 State House Station
Augusta, ME 04333
-or-
Secretary of State
http://www.maine.gov/sos/cec/rules/10/ch101.htm
The board hereby incorporates by reference into this
					 chapter pages 74a-74c of the State Medicaid Plan as specified in Section
					 1(9) of this
					 chapter. The state Medicaid plan may be obtained from-
Centers for Medicare and Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244-1850
The board hereby incorporates into this chapter by
					 reference into this chapter the DHHS Regulations Governing the Licensing and
					 Functioning of Skilled Nursing Facilities and Nursing Facilities /
					 Pharmaceutical Services specified in Section
					 1(9) of this
					 chapter. The rule may be obtained from:
Department of Health and Human Services
Division of Licensing and Regulatory Services
State House Station 11
Augusta, ME 04333
-or-
Maine Secretary of State
http://www.maine.gov/sos/cec/rules/10/ch110.htm
The board hereby incorporates into this chapter by
					 reference the reference standards of the United States Pharmacopeia specified
					 in Section
					 1(10) of this
					 chapter. The reference standards may be obtained from:
National Technical Information Service
5285 Port Royal Road
Springfield, VA 22161
(703) 605-6400
-or-
U.S. Pharmacopeial Convention
www.usp.org
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 31 - PRACTICE OF FRAUD OR DECEIT › Section 392-5-31-1 - Practice of Fraud or Deceit in Obtaining a License or Registration

Current through 2024-29, July 17, 2024
The practice of fraud or deceit in obtaining a license or
					 registration includes, but is not limited, to:
1. Falsification or misrepresentation of the
				  education or experience of the applicant;
2. Falsification or misrepresentation of a
				  recommendation or report from a preceptor;
3. Cheating on a license
				  examination;
4. Intentionally
				  withholding or misrepresenting any information requested on an application,
				  including any information regarding criminal or disciplinary action taken by
				  any state against an applicant; or
5. Impersonating another applicant.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 31 - PRACTICE OF FRAUD OR DECEIT › Section 392-5-31-2 - Practice of Fraud or Deceit in the Practice of Pharmacy

Current through 2024-29, July 17, 2024
The practice of fraud or deceit in the practice of
					 pharmacy includes, but is not limited, to:
1. Intentionally practicing or attempting to
				  practice, or aiding another to practice, beyond the scope of the license or
				  registration held;
2. Intentionally
				  misrepresenting the type or status of license or registration held or
				  qualifications to practice;
3.
				  Committing or aiding another to commit fraud, deceit or corruption in billing,
				  payment or insurance reimbursement procedures; or
4. Impersonating another licensee.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 32 - ISSUANCE OF CITATIONS › Section 392-5-32-1 - List of Violations

Current through 2024-29, July 17, 2024
An inspector may issue citations for the violations listed
					 in Appendix A to this chapter upon personal observation or discovery of the
					 violation charged. The fine for each violation is $200.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 32 - ISSUANCE OF CITATIONS › Section 392-5-32-2 - Service of Citation; Notice to Owner

Current through 2024-29, July 17, 2024
The citation may be served on an individual licensee by
					 hand delivery of the citation to the licensee or to a responsible employee at
					 the drug outlet where the licensee practices pharmacy. The citation may be
					 served on a drug outlet licensee by hand delivery of the citation to a
					 responsible employee at the drug outlet. The inspector shall mail or deliver in
					 hand a copy of the citation to the owner or designated agent of the drug outlet
					 at which the violation occurred.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 32 - ISSUANCE OF CITATIONS › Section 392-5-32-3 - Right to Hearing

Current through 2024-29, July 17, 2024
The citation shall inform the licensee that the licensee
					 may pay the fine or may request a hearing before the board regarding the
					 violation. If the licensee requests a hearing, the citation shall be processed
					 in the same manner as a complaint for purposes of Chapter 28 of the board's
					 rules, entitled "Enforcement and Disciplinary Procedures," except that the
					 licensee's written response to the citation must be filed with the board along
					 with the request for hearing.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 32 - ISSUANCE OF CITATIONS › Section 392-5-32-4 - Time for Payment or Request for Hearing

Current through 2024-29, July 17, 2024
The licensee shall either pay the fine or request a
					 hearing within 30 days following issuance of the citation. Failure to take
					 either action within this 30 day period is a violation of the board's rules
					 that may subject the licensee to further disciplinary action by the board,
					 including but not limited to an additional fine and possible action against the
					 license.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 32 - ISSUANCE OF CITATIONS › Section 392-5-32-5 - Board Action Following Hearing

Current through 2024-29, July 17, 2024
The board may not impose a penalty following hearing other
					 than $200, and may not assess costs otherwise authorized by
					  10
					 M.R.S.A. §8003-D.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 32 - ISSUANCE OF CITATIONS › Section 392-5-32-6 - Filing a Complaint Instead of Issuing a Citation

Current through 2024-29, July 17, 2024
Nothing in this chapter shall prohibit an inspector or
					 other representative of the board from filing a complaint pursuant to Chapter
					 28 , Section
					 2 of the board's rules in lieu of a
					 citation for a violation listed in Appendix A to this chapter.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 32 - ISSUANCE OF CITATIONS › Section 392-5-32-7 - Citation Violations not Reportable

Current through 2024-29, July 17, 2024
Fines paid in response to citations issued pursuant to
					 this chapter shall not be reported to the National Association of Boards of
					 Pharmacy or to any other person, organization or regulatory body that is not a
					 part of Maine state government.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 32 - ISSUANCE OF CITATIONS › Section 392-5-32-8 - Citation Violations Constitute Discipline

Current through 2024-29, July 17, 2024
Fines paid in response to citations issued pursuant to
					 this chapter constitute discipline. The citations and records of fines paid
					 shall be maintained by the Office of licensing and Registration and shall be
					 treated as public records to the extent permitted by law.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 33 - ACCESS TO CERTAIN MEDICATIONS BY CERTIFIED MIDWIVES › Section 392-5-33-1 - Scope

Current through 2024-29, July 17, 2024
This chapter applies solely to the acquisition and
					 administration of certain noncontrolled drugs and substances by certified
					 midwives.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 33 - ACCESS TO CERTAIN MEDICATIONS BY CERTIFIED MIDWIVES › Section 392-5-33-2 - Sale of Drugs to Certified Midwives

Current through 2024-29, July 17, 2024
1.
Limited Formulary
A pharmacist may elect to sell to a certified midwife
					 without a prescription only the following noncontrolled drugs and
					 substances:
A. Oxygen, USP.;
B. Oxytocin injection 10 units/ml 1 ml,
				  excluding the oxytocic drug methergine, for the sole purpose of postpartum
				  control of maternal hemorrhage;
C.
				  Phytonadione injection 2 mg/ml 0.5 ml (Vitamin K neonatal
				  concentration);
D. Erythromycin
				  ophthalmic ointment (for eye prophylaxis); and
E. The following local anesthetics and
				  numbing agents for repair of lacerations:
(1)
				  Lidocaine injection 1%;
(2)
				  Bupivacaine injection 0.25%;
(3)
				  Lidocaine topical spray 10%;
(4)
				  Benzocaine topical spray 20%; and
(5) Lidocaine 4% topical anesthetic
				  cream
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 33 - ACCESS TO CERTAIN MEDICATIONS BY CERTIFIED MIDWIVES › Section 392-5-33-3 - Administration of Certain Noncontrolled Drugs and Substances by Certified Midwives; Further Distribution or Transfer Prohibited

Current through 2024-29, July 17, 2024
A certified midwife may administer the noncontrolled drugs
					 and substances listed in Section
					 2(1) of this chapter
					 only in the course of the practice of midwifery. A certified midwife may not
					 otherwise dispense, sell, give away or transfer the noncontrolled drugs or
					 substances.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 33 - ACCESS TO CERTAIN MEDICATIONS BY CERTIFIED MIDWIVES › Section 392-5-33-4 - Storage of Certain Noncontrolled Drugs and Substances by Certified Midwives

Current through 2024-29, July 17, 2024
A certified midwife shall store the noncontrolled drugs
					 and substances listed in Section
					 2(1) of this chapter
					 at appropriate temperatures and under appropriate conditions in accordance with
					 manufacturers' requirements in the labeling of such drugs and substances, or
					 with requirements in the current edition of an official compendium.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 33 - ACCESS TO CERTAIN MEDICATIONS BY CERTIFIED MIDWIVES › Section 392-5-33-5 - Records and Reporting

Current through 2024-29, July 17, 2024
1.
Purchase
				  and Destruction Records
A certified midwife shall keep a log of injectable
					 oxytocin and injectable vitamin K purchased by the midwife pursuant to this
					 chapter. For each such purchase the log shall note:
A. The date of purchase;
B. The name and address of the retail
				  pharmacy where the oxytocin or vitamin K was purchased;
C. The name of the selling
				  pharmacist;
D. The quantity and
				  dosage of oxytocin or vitamin K purchased;
E. The expiration date of the oxytocin or
				  vitamin K purchased; and
F. A
				  statement as to whether any quantity of the oxytocin or vitamin K remained
				  unused upon the expiration date and, if any, the date and manner of destruction
				  of the unused stock.
Purchase and destruction records must be maintained
					 separately from the administration records required by Section
					 5(2) of this
					 chapter.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 34 - LICENSURE OF RETAIL SUPPLIERS OF MEDICAL OXYGEN › Section 392-5-34-1-A - Authority

Current through 2024-29, July 17, 2024
A retail supplier of medical oxygen is a classification of
					 retail pharmacy regulated by the board pursuant to
					  32 MRSA
					 §13751(2)(A) and §
										13751(3).
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 34 - LICENSURE OF RETAIL SUPPLIERS OF MEDICAL OXYGEN › Section 392-5-34-2 - License Required

Current through 2024-29, July 17, 2024
1.
General
				  Requirement
Medical oxygen for use by a specific person may be sold at
					 retail only pursuant to a prescription from a practitioner. A retail supplier
					 of medical oxygen located within or outside Maine who sells or dispenses
					 medical oxygen to consumers who reside in Maine shall obtain a retail supplier
					 of medical oxygen license from the board. A retail supplier of medical oxygen
					 need not have a pharmacist in charge or a pharmacist.
2.
Exception for Licensed
				  Pharmacies
A pharmacy licensed by the board may sell medical oxygen at
					 retail without need of a license under this chapter.
3.
Sales for Emergency Medical Use -
				  Dual Licensure Not Required
A retail supplier of medical oxygen licensed under this
					 chapter who sells oxygen for emergency medical use to a licensed practitioner
					 or licensed health care facility need not, by virtue of those sales alone, be
					 licensed as a wholesaler pursuant to Chapter 12 of the board's
					 rules.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 34 - LICENSURE OF RETAIL SUPPLIERS OF MEDICAL OXYGEN › Section 392-5-34-3 - Temporary Licensure

Current through 2024-29, July 17, 2024
1. Timeline
The board may issue a temporary license as a retail
					 supplier of medical oxygen upon receipt of an application for licensure
					 submitted pursuant to Section
					 4 of this chapter. The application
					 must demonstrate the applicant's prima facie eligibility for licensure. The
					 temporary license expires 90 days from the date of issuance. Within the first
					 60 days of temporary licensure, a temporary licensee shall complete the
					 application to the satisfaction of the board. The board will act on
					 timely-completed applications for licensure within the 90-day period of the
					 temporary license.
2.
				  Limitation
A temporary license may not be extended or renewed. A
					 person may not receive a temporary license more than once.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 34 - LICENSURE OF RETAIL SUPPLIERS OF MEDICAL OXYGEN › Section 392-5-34-5 - Prescription Drug Order

Current through 2024-29, July 17, 2024
Each retail sale of medical oxygen must be authorized by a
					 prescription from a practitioner. A retail supplier of medical oxygen may fill
					 a prescription for the length of medical need authorized by the prescribing
					 practitioner. If the length of medical need is not specified, the prescription
					 drug order is valid for 15 months.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 34 - LICENSURE OF RETAIL SUPPLIERS OF MEDICAL OXYGEN › Section 392-5-34-6 - Maine Rx Plus Prescriptions

Current through 2024-29, July 17, 2024
With each prescription dispensed to a participant in the
					 Maine Rx Plus Program,
					  22 MRSA
					 §2681 et seq., the retail supplier of
					 medical oxygen shall disclose to the purchaser in writing the usual and
					 customary price of the prescription to a purchaser not covered by or enrolled
					 in any type of health insurance, prescription drug benefit or 3d party payor
					 plan, public or private, and the amount of savings provided to the purchaser as
					 a result of the Maine Rx Plus Program. No proprietary information need be
					 disclosed pursuant to this subsection.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 34 - LICENSURE OF RETAIL SUPPLIERS OF MEDICAL OXYGEN › Section 392-5-34-7 - Patient Records

Current through 2024-29, July 17, 2024
A retail supplier of medical oxygen shall keep in written
					 or any electronic format prescriptions, invoices and delivery records for each
					 patient served. Records must be retained for 3 years from the date of last
					 delivery to a patient and must be produced to an inspector or representative of
					 the board upon request.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 34 - LICENSURE OF RETAIL SUPPLIERS OF MEDICAL OXYGEN › Section 392-5-34-8 - Compliance with Current Good Manufacturing Practices; Incorporation by Reference

Current through 2024-29, July 17, 2024
1. Current Good
				  Manufacturing Practices
A retail supplier of medical oxygen that manufactures,
					 processes, packages or holds oxygen as defined in the Federal Food, Drug, and
					 Cosmetic Act and its implementing rules shall comply with the current good
					 manufacturing practices promulgated by the Food and Drug Administration in 21
					 CFR Parts 210 and 211 (April 1, 2012 edition).
2.
Incorporation by Reference
The board hereby incorporates the following documents by
					 reference into this chapter:
A. Title
				  21 CFR Part 210, "Current Good Manufacturing Practice in Manufacturing,
				  Processing, Packing or Holding of Drugs; General" promulgated by the U.S. Food
				  and Drug Administration (April 1, 2012 edition). This document is available
				  from the FDA on line at:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm
This document may also be obtained from the State Law
					 Library, State House, Augusta, Maine, tel. (207) 287-1600.
B. Title 21 CFR Part 211, "Current Good
				  Manufacturing Practice for Finished Pharmaceuticals" promulgated by the U.S.
				  Food and Drug Administration (April 1, 2012 edition). This document is
				  available from the FDA on line at:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm
This document may also be obtained from the State Law
					 Library, State House, Augusta, Maine, tel. (207) 287-1600.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 34 - LICENSURE OF RETAIL SUPPLIERS OF MEDICAL OXYGEN › Section 392-5-34-9 - Packaging, Storage and Labeling

Current through 2024-29, July 17, 2024
A retail supplier of medical oxygen shall store, package
					 and label oxygen in accordance with the requirements of the U.S.
					 Pharmacopeia.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 35 - LICENSURE OF EXTENDED HOSPITAL PHARMACIES › Section 392-5-35-1 - Authority

Current through 2024-29, July 17, 2024
An extended hospital pharmacy is a classification of retail
					 pharmacy regulated by the board pursuant to
					  32 MRSA
					 §13751(2)(A) and §
										13751(3).
					 An extended hospital pharmacy must be licensed pursuant to this
					 chapter.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 35 - LICENSURE OF EXTENDED HOSPITAL PHARMACIES › Section 392-5-35-2 - Coordination With Hospital Licensure by DHHS

Current through 2024-29, July 17, 2024
Licensure of an extended hospital pharmacy under this
					 chapter is intended to authorize activities that are deemed by DHHS as being
					 outside the scope of the pharmaceutical services encompassed by its licensure
					 of the hospital in which the extended hospital pharmacy is
					 located.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 35 - LICENSURE OF EXTENDED HOSPITAL PHARMACIES › Section 392-5-35-3 - Scope of License

Current through 2024-29, July 17, 2024
An extended hospital pharmacy may dispense, deliver and
					 distribute prescription drugs only to the following persons:
1.
Nursing Home Residents
Residents of a nursing facility or skilled nursing facility
					 that is affiliated with the hospital in which the extended hospital pharmacy is
					 located.
2.
Employees, Students, Medical Staff and Dependents
Employees, students and medical staff of a nursing facility
					 or skilled nursing facility that is affiliated with the hospital in which the
					 extended hospital pharmacy is located, and their dependents, for their personal
					 use.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 35 - LICENSURE OF EXTENDED HOSPITAL PHARMACIES › Section 392-5-35-4 - Applicability of DHHS Rules

Current through 2024-29, July 17, 2024
An extended hospital pharmacy that dispenses to residents
					 of an affiliated nursing home must comply with Chapter 110, Chapter 17, of
					 DHHS' rules, "Regulations Governing the Licensing and Functioning of Skilled
					 Nursing Facilities and Nursing Facilities / Pharmaceutical Services" (February
					 1, 2001 edition, as amended effective October 15, 2004.) The pharmacist in
					 charge of the extended hospital pharmacy has the responsibilities of the
					 pharmacist consultant described in Chapter 110, Chapter 17.
The board incorporates Chapter 110, Chapter 17, of DHHS'
					 rules, "Regulations Governing the Licensing and Functioning of Skilled Nursing
					 Facilities and Nursing Facilities / Pharmaceutical Services" (February 1, 2001
					 edition, as amended effective October 15, 2004) into this chapter by reference.
					 A copy of Chapter 110, Chapter 17 may be obtained from:
Department of Health and Human Services
Division of Licensing and Regulatory Services
State House Station 11
Augusta, ME 04333
-or-
Maine Secretary of State
http://www.maine.gov/sos/cec/rules/10/ch110.htm
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 35 - LICENSURE OF EXTENDED HOSPITAL PHARMACIES › Section 392-5-35-6 - Maine Rx Plus Prescriptions

Current through 2024-29, July 17, 2024
With each prescription dispensed to a participant in the
					 Maine Rx Plus Program,
					  22 MRSA
					 §2681 et seq., the extended hospital
					 pharmacy shall disclose to the purchaser in writing the usual and customary
					 price of the prescription to a purchaser not covered by or enrolled in any type
					 of health insurance, prescription drug benefit or 3d party payor plan, public
					 or private, and the amount of savings provided to the purchaser as a result of
					 the Maine Rx Plus Program. No proprietary information need be disclosed
					 pursuant to this subsection.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 36 - LICENSURE OF OPIOID TREATMENT PROGRAMS › Section 392-5-36-1 - Authority

Current through 2024-29, July 17, 2024
An opioid treatment program is a classification of retail
					 pharmacy regulated by the board pursuant to
					 32 MRSA
					 §13751(2)(A) and §
										13751(3).
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 36 - LICENSURE OF OPIOID TREATMENT PROGRAMS › Section 392-5-36-2 - License Required; Coordination With State and Federal Regulatory Requirements

Current through 2024-29, July 17, 2024
An opioid treatment program must obtain a license from the
					 board. This chapter applies to opioid treatment programs that are-
Certified or provisionally certified by the U.S.
						Department of Health and Human Services, Substance Abuse and Mental Health
						Services Administration pursuant to 42 CFR Part 8; and
										Licensed by the Maine Department of Health and Human
						Services, Division of Licensing and Regulatory Services pursuant to 14-118 CMR
						Chapter 5, Section 19.8.
An opioid treatment program licensed by the board pursuant
					 to this chapter must furnish copies of its federal DHHS certification, DEA
					 number and state DHHS license to the board prior to opening for
					 operation.
Maintenance of federal DHHS certification and state DHHS
					 licensure as set forth above is an ongoing requirement of licensure by the
					 board. Any loss or lapse of federal DHHS certification or state DHHS licensure
					 may result in disciplinary action by the board.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 36 - LICENSURE OF OPIOID TREATMENT PROGRAMS › Section 392-5-36-4 - Pharmacist in Charge

Current through 2024-29, July 17, 2024
1.
Generally
Dispensing of opioids and other prescription drugs must be
					 conducted under the indirect supervision of a licensed pharmacist who has
					 registered with the board as the pharmacist in charge of the opioid treatment
					 program. No opioid treatment program may operate without a pharmacist in
					 charge.
2.
Responsibilities
The pharmacist in charge is responsible legally and
					 professionally for all activities related to the practice of pharmacy within
					 the opioid treatment program for which the licensee is registered as pharmacist
					 in charge, and for the opioid treatment program's compliance with the
					 provisions of the Maine Pharmacy Act, the rules of the board, and the federal
					 and state laws and rules specified in Chapter 29, Section 1 of the board's
					 rules.
The pharmacist in charge is responsible for ensuring that
					 doses of opiate agonist treatment medications are prepared in properly labeled,
					 patient-specific containers for delivery of such drugs to patients for
					 consumption away from the facility. The responsibilities of the pharmacist in
					 charge also include, but are not limited to:
A. The opioid treatment program's procedures
				  for the procurement, storage, compounding and dispensing of drugs;
B. The recordkeeping systems required in the
				  practice of pharmacy for the purchase, possession, storage and repackaging of
				  drugs; and C. Ensuring that the dispensing area is operating in conformance
				  with good pharmaceutical practices.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 36 - LICENSURE OF OPIOID TREATMENT PROGRAMS › Section 392-5-36-5 - Operational Requirements

Current through 2024-29, July 17, 2024
1.
Security
The opioid treatment program must comply at all times with
					 the alarm and security camera requirements of Chapter 13, Section 6 of the
					 board's rules.
2.
Cleanliness and Sanitation
A. The
				  opioid treatment program must at all times be operated in a clean and sanitary
				  manner in compliance with all federal, state and local health laws. The program
				  must:
(1) Keep walls, ceilings, windows and
				  floors clean and in good repair;
(2) Have a sufficient number of waste
				  receptacles in the dispensing and drug storage areas;
(3) Keep equipment clean and stored in an
				  orderly manner; and
(4) Have
				  adequate restroom facilities for employees and patients.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 37 - LICENSURE OF STERILE COMPOUNDING PHARMACIES › Section 392-5-37-1 - Authority

Current through 2024-29, July 17, 2024
A sterile compounding pharmacy is a classification of
					 retail pharmacy regulated by the board pursuant to
					  32 MRSA
					 §13751(2)(A) and §
										13751(3).
					 A sterile compounding pharmacy must be licensed by the board pursuant to this
					 chapter. For pharmacies that hold or apply for a general retail pharmacy
					 license or closed-shop pharmacy license, the sterile compounding pharmacy
					 license may be issued in the form of an endorsement to the general retail or
					 closed-shop pharmacy license.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 37 - LICENSURE OF STERILE COMPOUNDING PHARMACIES › Section 392-5-37-2 - Scope of License Requirement

Current through 2024-29, July 17, 2024
A sterile compounding pharmacy must be licensed by the
					 board pursuant to this chapter. A non-sterile compounding pharmacy must be
					 licensed as a general retail pharmacy pursuant to Chapter 8 of the board's
					 rules or a closed-shop pharmacy pursuant to Chapter 38 of the board's
					 rules.
Code of Maine Rules › 02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION › 392 - MAINE BOARD OF PHARMACY › Part 5 - LICENSE DENIAL AND PROFESSIONAL DISCIPLINE › Chapter 37 - LICENSURE OF STERILE COMPOUNDING PHARMACIES › Section 392-5-37-4 - Pharmacist in Charge

Current through 2024-29, July 17, 2024
The pharmacist in charge is responsible legally and
					 professionally for all activities related to the practice of pharmacy within
					 the sterile compounding pharmacy for which the licensee is registered as
					 pharmacist in charge, and for the pharmacy's compliance with the provisions of
					 the Maine Pharmacy Act, the rules of the board, and the federal and state laws
					 and rules and other codes specified in Chapter 29, Section
					 1 of the board's rules. Unless waived
					 by the board for good cause shown, the pharmacist in charge shall practice at
					 the sterile compounding pharmacy for a minimum of 30 hours per week or 50% of
					 the hours the pharmacy is open, whichever is less. However, a waiver from the
					 30 hour/50% requirement will be automatically approved upon request by a
					 pharmacist to the extent authorized by Chapter 13, Section
					 3(4) of the board's
					 rules.
[NOTE: Chapter 13, Section
					 3(4) provides in
					 pertinent part that "[a] request to serve as pharmacist in charge of a retail
					 pharmacy, closed pharmacy and/or sterile compounding pharmacy at the same
					 location will be approved automatically subject to disciplinary
					 review."]
The responsibilities of the pharmacist in charge include,
					 but are not limited to:
1. The
				  pharmacy's procedures for the procurement, storage, compounding and dispensing
				  of drugs;
2. The recordkeeping
				  systems required in the practice of pharmacy for the purchase, sale,
				  possession, storage and repackaging of drugs;
3. Notifying the board of termination of
				  status as pharmacist in charge via letter, fax or email within 7 days of the
				  termination;
4. The supervision of
				  pharmacy technicians and performance of administrative responsibilities
				  relating to pharmacy technicians as required by Chapter 7 of the board's rules;
				  and
5. Ensuring that each
				  pharmacist employed at the pharmacy for which the pharmacist in charge is
				  responsible is licensed with the board.